[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447598":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":45,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":10,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (medical records review)",null,"Patients' medical records are reviewed.",[13],"Other: Electronic Health Record Review",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Electronic Health Record Review","Medical records are reviewed",[9],[20],{"name":21,"affiliation":5,"role":22},"Nicolas L Palaskas","PRINCIPAL_INVESTIGATOR",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-95.36327,29.76328,{"lat":36,"lon":35},[39,44],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"Nicolas L. Palaskas","CONTACT","713-563-3532","nlpalaskas@mdanderson.org",{"name":40,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100447598",false,"NCT05108519","Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","Inclusion Criteria:\n\n* Patients must be able to understand and be willing to sign a written informed consent document\n* Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy","ALL",{"count":55,"type":56},170,"ESTIMATED","OBSERVATIONAL","This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.",[60,61],"Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","2026-02-17",{"date":64,"type":65},"2026-02-19","ACTUAL",{"date":67,"type":65},"2019-04-08",{"date":69,"type":56},"2027-02-02",{"name":5,"class":6},1]